Monopar Therapeutics Inc.

Monopar Therapeutics Inc.verified

MNPR

Price:

$2.39

Market Cap:

$8.41M

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimm...[Read more]

Industry

Biotechnology

IPO Date

2019-12-19

Stock Exchange

NASDAQ

Ticker

MNPR

The Enterprise Value as of September 2024 (TTM) for Monopar Therapeutics Inc. (MNPR) is 2.29M

According to Monopar Therapeutics Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 2.29M. This represents a change of -91.64% compared to the average of 27.43M of the last 4 quarters.

Monopar Therapeutics Inc. (MNPR) Historical Enterprise Value (quarterly & annually)

How has MNPR Enterprise Value performed in the past?

The mean historical Enterprise Value of Monopar Therapeutics Inc. over the last ten years is 781.03M. The current 2.29M Enterprise Value has changed -70.63% with respect to the historical average. Over the past ten years (40 quarters), MNPR's Enterprise Value was at its highest in in the June 2018 quarter at 1.52B. The Enterprise Value was at its lowest in in the June 2016 quarter at 0.

Quarterly (TTM)
Annual

Average

781.03M

Median

865.56M

Minimum

-2565937.00

Maximum

1.40B

Monopar Therapeutics Inc. (MNPR) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Monopar Therapeutics Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 0.15%

Maximum Annual Enterprise Value = 1.40B

Minimum Annual Increase = -101.80%

Minimum Annual Enterprise Value = -2565937.00

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023-2565937.00-101.80%
2022142.53M-20.76%
2021179.88M-43.54%
2020318.59M-63.19%
2019865.56M-37.00%
20181.37B0.15%
20171.37B-0.50%
20161.38B-1.58%

Monopar Therapeutics Inc. (MNPR) Average Enterprise Value

How has MNPR Enterprise Value performed in the past?

The current Enterprise Value of Monopar Therapeutics Inc. (MNPR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

106.61M

5-year avg

300.80M

10-year avg

781.03M

Monopar Therapeutics Inc. (MNPR) Enterprise Value vs. Peers

How is MNPR’s Enterprise Value compared to its peers?

Monopar Therapeutics Inc.’s Enterprise Value is less than Anebulo Pharmaceuticals, Inc. (41.53M), less than Acrivon Therapeutics, Inc. Common Stock (208.47M), less than PMV Pharmaceuticals, Inc. (40.92M), greater than Molecular Partners AG (-1929773.37), less than Mineralys Therapeutics, Inc. (490.57M), less than Candel Therapeutics, Inc. (194.11M), less than Acurx Pharmaceuticals, Inc. (25.80M), less than Enochian Biosciences, Inc. (99.82M), less than scPharmaceuticals Inc. (258.51M), less than DiaMedica Therapeutics Inc. (158.60M), greater than Scopus BioPharma Inc. (-349472.00), greater than Pasithea Therapeutics Corp. (-3592870.00), less than AN2 Therapeutics, Inc. (3.67M), less than Pharvaris N.V. (587.59M), less than PepGen Inc. (241.09M), less than Aerovate Therapeutics, Inc. (24.46M), less than Adagene Inc. (40.66M), less than Rezolute, Inc. (237.24M),

Build a custom stock screener for Monopar Therapeutics Inc. (MNPR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Monopar Therapeutics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Monopar Therapeutics Inc. (MNPR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Monopar Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Monopar Therapeutics Inc.'s Enterprise Value?

What is the highest Enterprise Value for Monopar Therapeutics Inc. (MNPR)?

What is the 3-year average Enterprise Value for Monopar Therapeutics Inc. (MNPR)?

What is the 5-year average Enterprise Value for Monopar Therapeutics Inc. (MNPR)?

How does the current Enterprise Value for Monopar Therapeutics Inc. (MNPR) compare to its historical average?